Structure

InChI Key JRURYQJSLYLRLN-BJMVGYQFSA-N
Smiles CCN(CC)C(=O)/C(C#N)=C/c1cc(O)c(O)c([N+](=O)[O-])c1
InChI
InChI=1S/C14H15N3O5/c1-3-16(4-2)14(20)10(8-15)5-9-6-11(17(21)22)13(19)12(18)7-9/h5-7,18-19H,3-4H2,1-2H3/b10-5+

Physicochemical Descriptors

Property Name Value
Molecular Formula C14H15N3O5
Molecular Weight 305.29
AlogP 1.78
Hydrogen Bond Acceptor 6.0
Hydrogen Bond Donor 2.0
Number of Rotational Bond 5.0
Polar Surface Area 127.7
Molecular species ACID
Aromatic Rings 1.0
Heavy Atoms 22.0

Bioactivity

Mechanism of Action Action Reference
Catechol O-methyltransferase inhibitor INHIBITOR DailyMed
Protein: Catechol O-methyltransferase

Description: Catechol O-methyltransferase

Organism : Homo sapiens

P21964 ENSG00000093010
Assay Description Organism Bioactivity Reference
Inhibition of Catechol O-methyltransferase activity in SK-N-SH cells at a concentration of 100 nM None 77.0 %
Inhibition of Catechol O-methyltransferase activity in rat brain None 12.8 nM
Percent inhibition of Catechol O-methyltransferase activity in rat brain at dose of 30 mg/kg determined at 0.5 hr after its administration None 72.0 %
Percent inhibition of Catechol O-methyltransferase activity in rat brain at dose of 30 mg/kg determined at 3 hr after its administration None 30.0 %
Percent inhibition of Catechol O-methyltransferase activity in rat brain at dose of 30 mg/kg determined at 9 hr after its administration None 23.0 %
Percent inhibition of Catechol O-methyltransferase activity in rat liver at dose of 30 mg/kg determined at 0.5 hr after its administration None 98.0 %
Percent inhibition of Catechol O-methyltransferase activity in rat liver at dose of 30 mg/kg determined at 1 hr after its administration None 96.0 %
Percent inhibition of Catechol O-methyltransferase activity in rat liver at dose of 30 mg/kg determined at 3 hr after its administration None 86.0 %
Percent inhibition of Catechol O-methyltransferase activity in rat liver at dose of 30 mg/kg determined at 6 hr after its administration None 74.0 %
Percent inhibition of Catechol O-methyltransferase activity in rat liver at dose of 30 mg/kg determined at 9 hr after its administration None 25.0 %
Percent inhibition of Catechol O-methyltransferase activity in rat brain at dose of 30 mg/kg determined at 1 hr after its administration None 45.0 %
percent inhibition of Catechol O-methyltransferase activity in rat brain at dose of 30 mg/kg determined at 6 hr after its administration None 20.0 %
Percentage inhibitory activity against COMT at 100 nM in human neuroblastoma SK-N-SH cells Homo sapiens 77.0 %
Percentage inhibitory activity against COMT for 0.5h in homogenates of rat brain administered with 30mg/kg by Gastric tube Rattus norvegicus 72.0 %
Percentage inhibitory activity against COMT for 1h in homogenates of rat brain administered with 30mg/kg by Gastric tube Rattus norvegicus 45.0 %
Percentage inhibitory activity against COMT for 3h in homogenates of rat brain administered with 30mg/kg by Gastric tube Rattus norvegicus 30.0 %
Percentage inhibitory activity against COMT for 6h in homogenates of rat brain administered with 30 mg/kg by Gastric tube Rattus norvegicus 20.0 %
Percentage inhibitory activity against COMT for 9h in homogenates of rat brain administered with 30 mg/kg by Gastric tube Rattus norvegicus 23.0 %
Percentage inhibitory activity against COMT for 1h in homogenates of rat liver administered with 30 mg/kg by Gastric tube Rattus norvegicus 96.0 %
Percentage inhibitory activity against COMT for 6h in homogenates of rat liver administered with 30 mg/kg by Gastric tube Rattus norvegicus 74.0 %
Percentage inhibitory activity against COMT for 0.5h in homogenates of rat liver administered with 30mg/kg by Gastric tube Rattus norvegicus 98.0 %
Percentage inhibitory activity against COMT for 3h in homogenates of rat liver administered with 30 mg/kg by Gastric tube Rattus norvegicus 86.0 %
Percentage inhibitory activity against COMT for 9h in homogenates of rat liver administered with 30mg/kg by Gastric tube Rattus norvegicus 25.0 %
Inhibition of COMT in human SK-N-SH cells at 100 nM Homo sapiens 77.0 %
Inhibition of peripheral COMT in mouse liver at 30 mg/kg, po by gastric tube after 1 hr Mus musculus 76.0 %
Inhibition of central COMT in mouse brain at 30 mg/kg, po by gastric tube after 1 hr Mus musculus 23.0 %
Inhibition of peripheral COMT in mouse liver at 30 mg/kg, po by gastric tube after 6 hrs Mus musculus 26.0 %
Inhibition of central COMT in mouse brain at 30 mg/kg, po by gastric tube after 6 hrs Mus musculus 15.0 %
Inhibition of COMT in NMRI mouse liver homogenates assessed as metanephrine formation at 30 mg/kg, po measured after 6 hrs relative to control Mus musculus 93.6 %
Inhibition of COMT in Wistar rat liver homogenates assessed as metanephrine formation at 3 mg/kg, po measured after 3 hrs relative to control Rattus norvegicus 66.6 %
Inhibition of COMT in NMRI mouse liver homogenates assessed as metanephrine formation at 3 mg/kg, po measured after 3 hrs relative to control Mus musculus 79.8 %
Inhibition of Dengue virus NS2B-NS3 protease expressed in Escherichia coli BL21 lambda (DE3) using Abz-NleKRRS-3-(NO2)Y as substrate at 50 uM preincubated for 15 mins before substrate addition measured up to 15 mins by spectrofluorimetry Dengue virus 21.0 %
Inhibition of West Nile virus NS2B-NS3 protease expressed in Escherichia coli BL21 lambda (DE3) using Abz-GLKRGG-3-(NO2)Y as substrate at 50 uM preincubated for 15 mins before substrate addition measured up to 15 mins by spectrofluorimetry West Nile virus 32.4 %
Inhibition of human thrombin using Boc-VPR-AMC as substrate at 25 uM preincubated for 15 mins before substrate addition measured up to 10 mins by spectrofluorimetry Homo sapiens 21.9 %
Inhibition of Mycobacterium tuberculosis InhA at 80 uM using DD-CoA and NADH Mycobacterium tuberculosis 47.0 %
Inhibition of human recombinant His-tagged soluble COMT expressed in Escherichia coli BL21 using aesculetin as substrate after 60 mins by microplate assay in presence of SAM Homo sapiens 386.0 nM
Pharmacokinetic parameters for Enctacpone after single oral administartion of 200 and 800 mg Entacapone tablets to volunteers. Homo sapiens 65.0 % Pharmacokinetic parameters for Enctacpone after single oral administartion of 200 and 800 mg Entacapone tablets to volunteers. Homo sapiens 82.0 %
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of Caco-2 cells at 10 uM after 48 hours by high content imaging Homo sapiens -7.14 %
Inhibition of synthetic AcPHF6 peptide aggregation in pH 7.4 phosphate buffer assessed as reduction in fluorescence intensity at 50 uM and measured every minute over 2 hrs with 5 secs shaking prior to each reading by ThT fluorescence assay None 60.3 %
Inhibition of COMT (unknown origin) in presence of AdoMet and Esculetin by reaction kinetic model based assay relative to control Homo sapiens 60.0 nM
Inhibition of S-COMT in Wistar rat liver assessed as metanephrine formation preincubated for 20 mins followed by addition of adrenaline as substrate and SAM measured after 5 mins by chromatographic analysis Rattus norvegicus 34.45 nM
Inhibition of MB-COMT in Wistar rat brain assessed as metanephrine formation preincubated for 20 mins followed by addition of adrenaline as substrate and SAM measured after 15 mins by chromatographic analysis Rattus norvegicus 3.47 nM Inhibition of MB-COMT in Wistar rat brain assessed as metanephrine formation preincubated for 20 mins followed by addition of adrenaline as substrate and SAM measured after 15 mins by chromatographic analysis Rattus norvegicus 3.02 nM
SARS-CoV-2 3CL-Pro protease inhibition percentage at 20µM by FRET kind of response from peptide substrate Severe acute respiratory syndrome coronavirus 2 16.82 % SARS-CoV-2 3CL-Pro protease inhibition percentage at 20µM by FRET kind of response from peptide substrate Severe acute respiratory syndrome coronavirus 2 14.45 %
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging Chlorocebus sabaeus 0.23 % Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging Chlorocebus sabaeus 0.05 % Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging Chlorocebus sabaeus 0.23 % Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging Chlorocebus sabaeus 0.05 %
Inhibition of rat liver COMT using esculetin as substrate by fluorescence based spectrophotometry Rattus norvegicus 230.0 nM

Cross References

Resources Reference
ChEBI 4798
ChEMBL CHEMBL953
DrugBank DB00494
DrugCentral 1018
FDA SRS 4975G9NM6T
Human Metabolome Database HMDB0012226
Guide to Pharmacology 6647
KEGG C07943
PDB PD9
PharmGKB PA164748726
PubChem 5281081
SureChEMBL SCHEMBL34504
ZINC ZINC000035342787